I. Welcome

II. Introductions / Medicaid Updates

III. Overview of Panel Activities and Procedures

IV. Drug Class Reviews, Review of Public Comments and Public Testimony

NC Medicaid is beginning a new PDL Panel meeting policy in 2022. We will be moving to meeting two times per year (January and July), in addition to reviewing every PDL category at least once per calendar year. Public comments during the 45-day public comment period will still only be allowed for categories the State designates on the publicly posted document. Speakers at the PDL Panel meeting are only allowed for categories listed in the agenda for that meeting. The categories that are highlighted below are categories that have no State recommendations but are open for discussion. The following are considered the open categories for the 1/13/2022 meeting:

ALZHEIMER'S AGENTS

ANALGESICS
1. Opioid Long-Acting
2. Short-Acting Schedule III-IV Opioids and Opioid/Analgesic Combinations
3. NSAIDS
4. Neuropathic Pain

ANTICONVULSANTS
1. Second Generation

ANTI-INFECTIVES, SYSTEMIC
1. Lincosamides and Oxazolidinones
2. Nitromidazoles
3. Antifungals
4. Antivirals, Influenza

BEHAVIORAL HEALTH
1. Antidepressants, Other
2. Antihyperkinesis / ADHD
3. Antipsychotics; Injectable, Long-Acting
4. Atypical Antipsychotics; Oral / Topical

**CARDIOVASCULAR**
1. ACE Inhibitors
2. Beta Blockers
3. Coronary Vasodilators
4. Triglyceride Lowering Agents

**CENTRAL NERVOUS SYSTEM**
1. Antimigraine Agents
2. CGRP Blockers/Modulators PREVENTATIVE (New Category)
3. CGRP Blockers/Modulators ACUTE TREATMENT (New Category)
4. Anti-Parkinson and Restless Leg Syndrome Agents
5. Multiple Sclerosis, Oral
6. Sedative Hypnotics
7. Smoking Cessation

**ENDOCRINOLOGY**
1. Hypoglycemics; Injectable, Short-Acting Insulin
2. Hypoglycemics; Injectable, Long-Acting Insulin

**GASTROINTESTINAL**
1. Antiemetic and Antivertigo Agents
2. Bile Acid Salts
3. Selective Constipation Agents

**GENITOURINARY/RENAL**
1. Urinary Antispasmodics

**HEMATOLOGIC**
1. Colony Stimulating Factors

**OPHTHALMIC**
1. Allergic Conjunctivitis Agents
2. Antibiotics
3. Antibiotics-Steroid Combinations
4. Anti-Inflammatory
5. Anti-Inflammatory / Immunomodulator
6. Alpha 2 Adrenergic Agents
7. Beta Blocker Agents / Combinations
8. Carbonic Anhydrase Inhibitors / Combinations
9. Prostaglandin Agonists
10. Rho Kinase Modifiers / Combinations

**OSTEOPOROSIS**
1. Bone Resorption Suppression and Related Agents

**OTIC**
1. Antibiotics
2. Anti-Infectives and Anesthetics
3. Anti-Inflammatory

**RESPIRATORY**
1. Beta-Adrenergic Handheld, Long-Acting
2. Beta-Adrenergic Handheld, Short-Acting
3. Beta-Adrenergic, Nebulizer Agents
4. Beta-Adrenergic, Oral
5. Orally Inhaled Anticholinergics / COPD Agents
6. Inhaled Corticosteroids
7. Inhaled Corticosteroid Combinations
8. Intranasal Rhinitis Agents
9. Leukotriene Modifiers
10. Low Sedating Antihistamines
11. Low Sedating Antihistamine Combinations

**TOPICALS**
1. Acne Agents
2. Androgenic Agents
3. NSAIDs
4. Antibiotics
5. Antibiotics- Vaginal
6. Antifungals
7. Antiparasitics
8. Antivirals
9. Immunomodulators, Atopic Dermatitis
10. Imidazoquinolinamines
11. Psoriasis
12. Rosacea Agents
13. Steroids, Low Potency
14. Steroids, Medium Potency
15. Steroids, High Potency
16. Steroids, Very High Potency

**MISCELLANEOUS**
1. Antipsoriatrics, Oral
2. Epinephrine, Self-Injected
3. Estrogen Agents, Combinations
4. Progestational Agents
5. Estrogen Agents, Oral / Transdermal
6. Estrogen Agents, Vaginal Preparations
7. Glucocorticoid Steroids, Oral
8. Immunomodulators, Systemic
9. Immunosuppressants
10. Movement Disorders
11. Opioid Antagonists
12. Opioid Dependence
13. Skeletal Muscle Relaxants
14. Disposable Insulin Delivery Devices

**DIABETIC CONTINUOUS GLUCOSE MONITOR SUPPLIES**
1. Continuous Glucose Monitor Transmitters / Receivers / Readers
2. Continuous Glucose Monitor Sensors

**DIABETIC SUPPLIES**

**VARIOUS MEDICATIONS REMOVED FROM COVERAGE**

V. Closing comments and adjournment